Ausgewählte Publikationen

Hamann, U., Liu, X., Lange, S., Ulmer, H. U. and Scott RJ (2002) Contribution of BRCA2 germline mutations to hereditary breast/ovarian cancer in Germany. J. Med. Genet. 39:e12.

Hamann, U. (2004) Risikomodifizierende Faktoren bei Frauen mit einer hohen „Anfälligkeit“ für erblichen Brustkrebs. BIOspektrum, Sonderausgabe, 10. Jahrgang, S. 504 (Übersichtsartikel).

Rashid, M.U., Jakubowska, A., Justenhoven, C., Harth, V., Pesch, B., Baisch, C., Pierl, C. B., Brüning, T., Ko, Y., Benner, A., Wichmann, H.E., Brauch, H., Hamann, U. on behalf of the GENICA Network (2005) German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer. Eur. J. Cancer 41, 2896-2903.

Rashid, M.U., Zaidi, A., Torres, D., Sultan, F., Shakoori, A.R., Seidel-Renkert, A., Farooq, H., Amin, A., and Hamann, U. (2006) Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients. Int. J. Cancer 119, 2832-2839.

Torres, D., Rashid, M.U., Gil, F., Umana, A., Ramelli, G., Briceno, I., and Hamann, U. (2007) High percentage of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia, South America. Breast Cancer Res. Treat. 103, 225-232.

Jakubowska, A., Gronwald, J., Górski, B., Huzarski, T., Byrski, T., Benner, A., Lubiñski, J., Scott, R.J., and Hamann, U. (2007a) The 3´ untranslated region C>T polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation. Breast Cancer Res. Treat. 104, 67-74.

Jakubowska, A., Gronwald, J., Menkiszak, J., Górski, B., Huzarski, T., Byrski, T., Edler, L., Lubiñski, J., Scott, R.J., and Hamann, U. (2007b) Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks. Breast Cancer Res. Treat. 104, 299-308.

Jakubowska, A., Gronwald, J., Menkiszak, J., Górski, B., Huzarski, T., Byrski, T., Edler, L., Lubiñski, J., Scott, R.J., and Hamann, U. (2007c) Integrin ß3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk. J. Med. Genet. 44, 408-411.

Justenhoven, C., Hamann, U., Pierl, C.B., Baisch, C., Harth, V., Rabstein, S., Spickenheuer, A., Pesch, B., Brüning, T., Winter, S., Ko, Y.-D., Brauch, H. (2008) CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res. Treat., in press.

nach oben